Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: Clinical activity and modulation of angiogenesis and lymphangiogenesis factors

Clinical Cancer Research

Volumn 16, Issue 23, 2010, Pages 5862-5872

  Del Vecchio, Michele ^a   Mortarini, Roberta ^a   Canova, Stefania ^a,g   Di Guardo, Lorenza ^a   Pimpinelli, Nicola ^b   Sertoli, Mario R ^c   Bedognetti, Davide ^c   Queirolo, Paola ^d   Morosini, Paola ^e   Perrone, Tania ^f   Bajetta, Emilio ^a,h   Anichini, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e ROCHE MILANO RICERCHE   (Italy)

^f Scientific Direction   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h Ist di Sci Biomediche S Gerardo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANGIOGENIC FACTOR; BEVACIZUMAB; CYTOKINE; FOTEMUSTINE; INTERLEUKIN 10; INTERLEUKIN 12P70; VASCULOTROPIN A; VASCULOTROPIN C;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; LUNG EMBOLISM; LYMPHANGIOGENESIS; MALE; MELANOMA; MELANOMA CELL; METASTASIS; METRORRHAGIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

ADULT; AGED; ANGIOGENIC PROTEINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; FEMALE; HUMANS; LYMPHANGIOGENESIS; MALE; MELANOMA; MIDDLE AGED; NEOADJUVANT THERAPY; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; YOUNG ADULT;

EID: 78650337037     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2363     Document Type: Article

References (39)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010;363:711-23.
2. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-52.
3. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo controlled study of sorafenib in combination with carboplatin and paclitaxel as second line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30.
4. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2 and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:5748-54.
5. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 2004;1:39-43.
6. Punt CJ, Tol J. More is less-combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 2009;6:731-3.
7. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol 2010;28:3366-79.
8. McDermott DF, George DJ. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. Cancer Treat Rev 2010;36:216-23.
9. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovirin improves survival of patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.
10. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007;14:2367-76.
11. Perez DG, Suman VJ, Fitch TR, Amatruda T 3rd, Morton RF, Jilani SZ, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009;115:119-27.
12. De Rossi A, Rossi L, Laudisi A, Sini V, Toppo L, Marchesi F, et al. Focus on fotemustine. J Exp Clin Cancer Res 2006;25:461-8.
13. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25.
14. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L,Winans MT, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-a2b. Clin Cancer Res 2007;13:2422-28.
15. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high dose interleukin-2 therapy. J Clin Oncol 2009; 27:2645-52.
16. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004;23:5968-77.
17. Anichini A, Mazzocchi A, Fossati G, Parmiani G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. J Immunol 1989;142:3692-701.
18. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, et al. Mutually exclusive NRASq61R and BRAFV600E mutations at the single cell level in the same human melanoma. Oncogene 2006;25:3357-64.
19. Zanon M, Piris A, Bersani I, Vegetti C, Molla A, Scarito A, et al. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 2004;64:7386-94.
20. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008;62:779-86.
21. Deichmann M, Benner A, Waldmann V, Bock M, Jäckel A, Näher H. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma. J Exp Clin Cancer Res 2000;19:301-7.
22. Soffietti R, Rudà R, Trevisan E, Picco E, Guarneri D, Caroli M, et al. Phase II study of bevacizumab and nitrosurea in patients with recurrent malignant glioma: a multicenter Italian study. J Clin Oncol 2009;27Suppl 15:abstr 2012.
23. Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res. 2009;15:3495-502.
24. Terheyden P, Hofmann MA, Weininger M, Bröcker EB, Becker JC. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. J Cancer Res Clin Oncol 2007;133:897-901.
25. Streit M, Detmar M. Angiogenesis, lymphangiogenesis and melanoma metastasis. Oncogene 2003;22:3172-9.
26. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102:493-501.
27. Vihinen PP, Hernberg M, Vuoristo MS, Tyynelä K, Laukka M, Lundin J, et al. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha 2a as first line treatment in metastatic melanoma. Melanoma Res 2010;20:318-25.
28. Gonzales-Cao M, Viteri S, Diaz-Lagares A, González A, Redondo P, Nieto Y, et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 2008;74:12-6.
29. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 2006;16:405-11.
30. Scheibenbogen C, Möhler T, Haefele J, Hunstein W, Keilholz U. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 1995;5:179-81.
31. Kurschat P, Eming S, Nashan D, Krieg T, Mauch C. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br J Dermatol 2007;156:653-8.
32. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann N Y Acad Sci 2008;1131:225-34.
33. Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 2008;216:347-54.
34. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGF-C induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007;109:1010-17.
35. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009;15:114-23.
36. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12. Biological properties and clinical application. Clin Cancer Res 2007;13:4677-85.
37. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: acounterpoint. J Leukoc Biol 2005;78:1043-51.
38. Torisu-Itakura H, Lee JH, Huynh Y, Ye X, Essner R, Morton DL. Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother 2007;30:831-8.
39. Kohno T, Mizukami H, Suzuki M, Saga Y, Takei Y, Shimpo M, et al. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 2003;63:5091-4.